Alembic Pharmaceuticals Limited (NSE:APLLTD)
764.25
+6.75 (0.89%)
Apr 21, 2026, 3:20 PM IST
Alembic Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 18.76B INR in the quarter ending December 31, 2025, with 10.84% growth. This brings the company's revenue in the last twelve months to 72.67B, up 13.20% year-over-year. In the fiscal year ending March 31, 2025, Alembic Pharmaceuticals had annual revenue of 66.72B with 7.12% growth.
Revenue (ttm)
72.67B
Revenue Growth
+13.20%
P/S Ratio
2.05
Revenue / Employee
4.39M
Employees
16,571
Market Cap
148.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.72B | 4.43B | 7.12% |
| Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
| Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
| Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
| Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Gland Pharma | 61.13B |
| Strides Pharma Science | 47.26B |
| NATCO Pharma | 45.63B |
| Akums Drugs and Pharmaceuticals | 42.60B |
| Wockhardt | 31.74B |
| Eris Lifesciences | 30.65B |
Alembic Pharmaceuticals News
- 1 day ago - Pharma sector stocks today, April 20: Panacea Biotech falls 2.23%, Alembic Pharma down 2.20%, Strides Pharma gains 1.43% - Business Upturn
- 4 days ago - Pharma sector stocks today, April 17: Natco Pharma jumps 3.81%, Alembic Pharma up 2.14%, Strides Pharma rises 1.27% - Business Upturn
- 5 days ago - Alembic Pharma receives USFDA approval for Methotrexate injection - Business Upturn
- 5 days ago - Alembic Pharma receives USFDA approval for Methotrexate injection; stock trades steady - Business Upturn
- 5 days ago - Alembic Pharmaceuticals receives USFDA approval for methotrexate injection - Business Upturn
- 14 days ago - Alembic Pharmaceuticals receives USFDA approval for Dapagliflozin tablets with US$ 10.487 billion market size - Business Upturn
- 25 days ago - Alembic Pharmaceuticals receives USFDA approval for Paroxetine Extended-Release Tablets - Business Upturn
- 25 days ago - Pharma sector stocks today, March 27: Alembic falls 2.42%, Alembic Pharma down 1.58%, EMCURE Pharma surge 1.08% - Business Upturn